6.20

9.93% +0.56

After Hours: 6.20

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is currently priced at $6.20, with a 24-hour trading volume of 755.11K. It has seen a +9.93% increased in the last 24 hours and a +11.71% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.57 pivot point. If it approaches the $6.40 resistance level, significant changes may occur.

Previous Close:

$5.64

Open:

$5.79

24h Volume:

755.11K

Market Cap:

$197.23M

Revenue:

$25.18M

Net Income/Loss:

$-22.29M

P/E Ratio:

-5.2991

EPS:

-1.17

Net Cash Flow:

$-27.64M

1W Performance:

+16.98%

1M Performance:

+11.71%

6M Performance:

+103.95%

1Y Performance:

+42.69%

1D Range:

$5.79

$6.5336

52W Range:

$2.68

$8.2212

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

310-358-3200

Address

8840 Wilshire Boulevard, 2nd Floor, Beverly Hills, CA

Employee

Twitter

@Capricor

Next Earnings Date

2024-05-13

Latest SEC Filings

CAPR's Discussions on Twitter

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

Capricor Therapeutics (NASDAQ:CAPR) Now Covered by Oppenheimer - Defense World

Defense World

Capricor Therapeutics (NASDAQ:CAPR) Now Covered by Analysts at Oppenheimer - MarketBeat

MarketBeat

Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform - MSN

MSN

Equities Analysts Offer Predictions for Capricor Therapeutics Inc's FY2024 Earnings (NASDAQ:CAPR) - Defense World

Defense World

Capricor Therapeutics Inc to Post Q2 2024 Earnings of ($0.34) Per Share, HC Wainwright Forecasts (NASDAQ:CAPR) - Defense World

Defense World

How to Take Advantage of moves in (CAPR) - Stock Traders Daily

Stock Traders Daily

Capricor Therapeutics Inc Stock (CAPR) Financials Data

Capricor Therapeutics Inc (CAPR) Revenue 2024

CAPR reported a revenue (TTM) of $25.18 million for the quarter ending December 31, 2023.

Capricor Therapeutics Inc (CAPR) Net Income 2024

CAPR net income (TTM) was -$22.29 million for the quarter ending December 31, 2023, a +23.20% increase year-over-year.

Capricor Therapeutics Inc (CAPR) Cash Flow 2024

CAPR recorded a free cash flow (TTM) of -$27.64 million for the quarter ending December 31, 2023, a -1,876% decrease year-over-year.

Capricor Therapeutics Inc (CAPR) Earnings per Share 2024

CAPR earnings per share (TTM) was -$0.83 for the quarter ending December 31, 2023, a +29.66% growth year-over-year.

Capricor Therapeutics Inc Stock (CAPR) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Musket David B	Director	Apr 23 '24	Option Exercise	1.39	16,156	22,457	47,692
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Oct 23 '23	Option Exercise	1.39	2,178	3,027	2,381
Musket David B	Director	Oct 12 '23	Buy	2.75	410	1,128	31,536
COLLIER EARL M JR	Director	Oct 10 '23	Buy	2.83	10,000	28,300	26,856
Musket David B	Director	Oct 09 '23	Buy	2.82	5,083	14,334	31,126
Auwaerter Paul Gisbert	Director	Oct 06 '23	Buy	2.84	5,000	14,200	5,000
Musket David B	Director	Oct 04 '23	Buy	2.90	2,500	7,250	26,043
Litvack Frank	Director	Aug 14 '23	Option Exercise	1.39	20,748	28,840	137,633

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.